OpRegen®, retinal pigment epithelial (RPE) cells for treatment of retinal disease

OpRegen® are human embryonic stem cell-derived retinal pigment epithelial cells (RPEs). Using a patented technology, CellCure has developed a means of driving human embryonic stem cells into the rare RPE cell.These cells are indicated for treatment of age-related macular degeneration (AMD).